AuthorisedPhase I and Phase II (Integrated)- OtherInterventional

OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer

This research study, called OVACURE-2, is exploring a new way to treat advanced ovarian cancer (stage III or IV). It's testing a treatment called 'adoptive T cell therapy' alongside a small amount of a drug called ALDESLEUKIN. This therapy uses your body's own immune cells to fight cancer. The main goal is to see how safe this new treatment is and what side effects it might cause. Researchers are also looking at how this treatment affects various immune cells in the body. This is an early-stage study (Phase I and II), meaning it's one of the first times this specific combination is being tested in people.

At a glance

Status

Authorised

Phase

Phase I and Phase II (Integrated)- Other

Sponsor

Leids Universitair Medisch Centrum (LUMC)

Enrolment target

Start

03 Dec 2025

Ovarian carcinoma

What is this study about?

This study, named OVACURE-2, is investigating an innovative way to treat advanced ovarian cancer. Ovarian cancer is a serious illness, and doctors are always looking for better treatments, especially for later stages of the disease.

The treatment being tested is called 'adoptive T cell therapy.' This type of therapy works with your body's own immune system, which is its natural defense against illness. In this approach, doctors take out some of your immune cells (specifically, T cells) and prepare them in a lab to be better at fighting cancer. These specially trained cells are then given back to you. The study combines this T cell therapy with a low dose of another medicine called ALDESLEUKIN, which can help T cells grow and become more active.

This study is in its early stages (Phase I and II), which means it's one of the first times this specific combination of treatments is being tested in people. The main purpose is to understand how safe the treatment is and to identify any side effects. Researchers will also look at how these treatments affect different parts of your immune system. It's hoped that this research could lead to more effective treatments for ovarian cancer in the future.

Key takeaways

This study is testing a new immune-based treatment for advanced ovarian cancer.
It combines special immune cells with a low dose of ALDESLEUKIN.
The main goal is to check how safe this new treatment is.
It's for women aged 18 or over with stage III/IV ovarian cancer.
You would be receiving this treatment before other main treatments like surgery.

Who may be eligible?

This study is specifically for women and you need to be at least 18 years old to take part. There is no upper age limit mentioned.

You would be considered if you have ovarian cancer that is advanced, meaning it's at stage III or IV. This study is for women who are having their first treatment for ovarian cancer, also known as 'first line neoadjuvant therapy', which is treatment given before surgery.

There might be other health requirements or previous treatment restrictions that aren't listed here. If you're interested, your doctor would need to check all the detailed requirements to see if this study is suitable for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you female?
Are you 18 years old or older?
Have you been diagnosed with stage III or IV ovarian cancer?
Are you about to start your very first treatment for ovarian cancer (neoadjuvant therapy)?

Answer every question to see your result.

What does participation involve?

If you join this study, you would receive the new treatment which involves adoptive T cell therapy combined with low-dose ALDESLEUKIN. While the full details of what participation involves aren't provided here, clinical trials typically include regular visits to the hospital or clinic. During these visits, you can expect to have blood tests, physical examinations, and scans to monitor your health and how the treatment is working. Doctors will carefully track any side effects you might experience. You will also have follow-up appointments after treatment to see how you are doing in the long term. The total duration of participation isn't specified but typically involves an active treatment period followed by a follow-up period.

Potential risks and benefits

Like all medical treatments, this new therapy carries potential benefits and risks. The potential benefit is that this new combination treatment might be more effective against advanced ovarian cancer than current standard treatments. However, because this is an early-stage study, the main risk is experiencing side effects, which could be serious. Researchers will closely monitor you for any problems. You will be fully informed of all known potential risks and benefits before deciding to join, and you always have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands

Common questions

What is 'adoptive T cell therapy'?

It's a treatment where doctors take some of your own immune cells, teach them to fight cancer better in a lab, and then give them back to you.

What is ALDESLEUKIN?

ALDESLEUKIN is a medicine given in low doses with the T cell therapy to help your immune cells grow and become more active.

What does 'neoadjuvant therapy' mean?

It means the treatment is given before the main treatment, like surgery, to try and shrink the cancer first.

What are 'Phase I and Phase II' studies?

These are early stages of clinical trials. Phase I mainly checks safety and side effects, and Phase II then looks at whether the treatment shows promise and continues to monitor safety.

Can I stop participating in the study if I want to?

Yes, you have the right to leave the study at any point, and it won't affect your regular medical care.